Last reviewed · How we verify
Adezunap
Adezunap is a Small molecule drug developed by Apurano Pharmaceuticals GmbH. It is currently in Phase 3 development.
Adezunap (AP707) is being studied for its efficacy and tolerability in treating chronic back pain. According to ClinicalTrials.gov, Adezunap is being investigated as a potential treatment for chronic pain, chronic pain syndrome, pain, and pain syndrome.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Adezunap |
|---|---|
| Sponsor | Apurano Pharmaceuticals GmbH |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy (PHASE3)
- Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain (PHASE3)
- Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis (PHASE3)
- Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis (PHASE3)
- Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy (PHASE3)
- Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy (PHASE3)
- Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain (PHASE3)
- Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adezunap CI brief — competitive landscape report
- Adezunap updates RSS · CI watch RSS
- Apurano Pharmaceuticals GmbH portfolio CI
Frequently asked questions about Adezunap
What is Adezunap?
Who makes Adezunap?
What development phase is Adezunap in?
Related
- Manufacturer: Apurano Pharmaceuticals GmbH — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing